SER-100
Peptide
Evidence outlook · program status
Discontinued, for reasons the sponsor has not stated
SER-100 is Serodus's peptide licensed from Zealand Pharma (ZP120, a nociceptin/orphanin FQ receptor partial agonist); the CT.gov record NCT00283361 confirms the Zealand origin. Serodus took it into a Phase 2 study in isolated systolic hypertension that completed in 2014. Serodus's own website today enumerates its whole pipeline as two candidates, SER150 and SER140, both in diabetic kidney disease, and states the company is exploring options for an acquisition of that pipeline; SER-100 is not on it. Absence from a live company's own current pipeline supports discontinued, but nothing dates or explains the stop. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01987284 NCT01987284 · Isolated Systolic Hypertension This small randomized, placebo-controlled crossover trial gave SER-100 or placebo to patients with isolated systolic hypertension who already took at least one blood pressure medicine; 17 patients completed treatment. The primary measure was adverse events, which has no formal efficacy test, so there is no met or missed result for the primary endpoint. There were no serious or severe adverse events. As a secondary measure, SER-100 lowered daytime systolic blood pressure by 7.0 mm Hg and diastolic blood pressure by 3.8 mm Hg compared with placebo over two treatment days. The figures come from the peer-reviewed report of the trial in Clinical Pharmacology in Drug Development. Its registered primary outcome on ClinicalTrials.gov is "Number of participants with adverse events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT01987284 | 2 | Number of participants with adverse events (Up to 4 weeks) 2014-07 | Primary, adverse events up to 4 weeks: no serious or severe adverse events in the 17 patients who completed treatment; no formal comparison. Secondary, ambulatory blood pressure vs placebo over the 2 treatment days: systolic -7.0 mm Hg (P=0.0032); diastolic -3.8 mm Hg (P=0.0011). | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Competitive landscape
This drug's own stage for Hypertension: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| SER-100: this drug | Discontinued | Peptide | ORL-1 (nociceptin opioid-like receptor) | not yet graded | Featured results are safety only in this race | |
| Aprocitentan (Tryvio) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | Reliable signal | NCT03541174: Week 4 sitting systolic blood pressure change: -15.26 vs -11.47 mmHg placebo for aprocitentan 12.5 mg; difference -3.79 mmHg (p=0.0042). For aprocitentan 25 mg: -15.20 vs -11.47 mmHg placebo; difference -3.73 mmHg (p=0.0046). | |
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | Reliable signal | NCT06168409: Change in 24-hour ambulatory average SBP at week 12: -16.6 mmHg with baxdrostat vs -2.6 mmHg with placebo; between-group difference -14.0 mmHg (95% CI -17.2 to -10.8; p<0.0001). NCT06034743: Change From Baseline in Seated Systolic Blood Pressure for 2 mg Baxdrostat (At Week 12): Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg -15.7 mmHg (Standard Error 1) vs Double-Blind Treatment Period Weeks 0-12 Placebo -5.8 mmHg (Standard Error 1) | |
| Propranolol (Inderal LA) | Approved | Small molecule | Beta-1/beta-2 adrenergic receptors | not yet graded | No reviewed efficacy summary in this indication | |
| AD-209 | Phase 3 | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel / Na-Cl cotransporter | Partial signal | NCT06348576: Week-8 sitting systolic blood pressure: non-inferiority and superiority vs telmisartan 40 mg confirmed in the full analysis set (published Phase III, 2026-02-20). | |
| AGSAVI | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | Partial signal | No reviewed efficacy summary in this indication | |
| Amlodipine / Valsartan / Rosuvastatin (CJ-30060) | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | Partial signal | No reviewed efficacy summary in this indication | |
| DWC202206 + DWC202207 | Phase 3 | Small molecule | — | Partial signal | No reviewed efficacy summary in this indication | |
| Esaxerenone (Minnebro) | Phase 3 | Small molecule | Mineralocorticoid receptor | Partial signal | NCT02722265: Change from baseline in sitting SBP/DBP, overall population (n=368): -16.1/-7.7 mmHg at week 12, -18.9/-9.9 mmHg at week 28, -23.1/-12.5 mmHg at week 52 (all 95% CI given); monotherapy subgroup (n=245): -16.3/-7.0 mmHg at week 12, -23.7/-12.3 mmHg at week 52 NCT02807987: Change from baseline in sitting SBP/DBP at end of treatment (Week 12), add-on-to-ARB/ACEI group (n=58): -17.8 mmHg SBP (95% CI -21.0 to -14.7), -8.1 mmHg DBP (95% CI -9.7 to -6.5), p<0.001 | |
| Fimasartan / Atorvastatin / Ezetimibe (BR1017) | Phase 3 | Small molecule | AT1 receptor; NPC1L1; HMG-CoA reductase | Partial signal | NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025). | |
| Levamlodipine / Valsartan (SYH9056) | Phase 3 | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel (dual) | Partial signal | NCT06771245: Blood-pressure lowering significantly superior to levamlodipine or valsartan monotherapy (sponsor, 2026-06-16). | |
| Lorundrostat | Phase 3 | Small molecule | Aldosterone synthase (CYP11B2) | Reliable signal | NCT06153693: Launch-HTN: change from baseline in automated office SBP at Week 6, lorundrostat 50 mg vs placebo: -16.9 mmHg absolute reduction; -9.1 mmHg placebo-adjusted reduction (p<0.0001) NCT05769608: Placebo-adjusted change in 24-hour average ambulatory SBP at Week 12: -7.9 mmHg (lorundrostat 50 mg arm) | |
| Olmesartan / Rosuvastatin (DWJ1276) (Olostar) | Phase 3 | Small molecule | Angiotensin II receptor / HMG-CoA reductase | Partial signal | NCT01764295: LDL-C percent change from baseline at week 8 (LS mean, SE): DWJ1276 (FDC) -52.3% (2.8%) vs olmesartan alone -0.6% (3.5%) vs rosuvastatin alone -46.9% (3.5%) vs placebo -3.2% (3.9%); FDC vs olmesartan difference -51.7% (95% CI -59.8% to -43.6%, P<0.0001). | |
| Orforglipron (Foundayo) | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| QR12000 | Phase 3 | Small molecule | AT1R; neprilysin | Partial signal | No reviewed efficacy summary in this indication | |
| Sacubitril / Valsartan (Entresto) | Phase 3 | Small molecule | Neprilysin + Angiotensin II receptor (dual) | Partial signal | NCT01599104: Mean sitting systolic BP reduction from baseline at week 8 vs olmesartan (LCZ696/Entresto, Japanese essential hypertension): sacubitril/valsartan 200mg difference -5.01 mmHg (95% CI -6.95 to -3.06, P<0.001 for noninferiority and superiority); 400mg difference -6.97 mmHg (95% CI -8.92 to -5.03, P<0.001). NCT01593787: 43.8% (14/32) of patients reported at least one adverse event (mild severity; 0% serious AEs, 0% deaths); mean sitting SBP reduction 20.5±11.3 mmHg and mean sitting DBP reduction 8.3±6.3 mmHg from baseline to Week 8 (Total LCZ696 group, N=32); geometric mean UACR reduction 15.1%. | |
| Safiglipron (HRS-7535) | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| SAL0120 | Phase 3 | Small molecule | Endothelin receptor type A (ETA) | not yet graded | No reviewed efficacy summary in this indication | |
| Valsartan / Amlodipine / Chlorthalidone (AJU-C52) | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | Reliable signal | NCT06416865: Change in MSSBP from baseline to week 8: between-group difference of -10.99 (valsartan/amlodipine/chlorthalidone vs valsartan/amlodipine control) | |
| Vicadrostat | Phase 3 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| Zilebesiran | Phase 3 | RNA / oligonucleotide | Angiotensinogen (AGT) | Reliable signal | NCT04936035: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM (Baseline and Month 3): Placebo 6.8 millimeters of mercury (mmHg) ± 1.58 vs Zilebesiran 150 mg Q6M -7.3 millimeters of mercury (mmHg) ± 1.49 vs Zilebesiran 300 mg Q6M and Q3M -10.0 millimeters of mercury (mmHg) ± 1.05 vs Zilebesiran 600 mg Q6M -8.9 millimeters of mercury (mmHg) ± 1.52; p=<0.0001 (Placebo vs Zilebesiran 300 mg Q6M and Q3M), p=<0.0001 (Placebo vs Zilebesiran 600 mg Q6M) | |
| HRS-9563 | Phase 2 | RNA / oligonucleotide | AGT (angiotensinogen) mRNA | not yet graded | No reviewed efficacy summary in this indication | |
| IBI3016 | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | not yet graded | No reviewed efficacy summary in this indication | |
| QCZ484 | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | not yet graded | No reviewed efficacy summary in this indication | |
| QLS1410 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| RTN-001 | Phase 2 | Small molecule | PDE5 | not yet graded | No reviewed efficacy summary in this indication | |
| SAL0140 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| Tonlamarsen | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | Partial signal | NCT06864104: Co-primary 1, plasma angiotensinogen change to week 20: monthly tonlamarsen -67.2% vs single dose then placebo -23.0% (LS mean difference -44.1%, 97.5% CI -51.9% to -36.4%; P<0.0001), met. Co-primary 2, office systolic BP change to week 20: -6.7 vs -6.7 mm Hg (LS mean difference -0.1 mm Hg; P=0.97), missed. NCT05314439: (-6% v. -79%, PBO v. 90 mg, p=0.001); median AGT reductions (-5% v. -86%, PBO v. 90 mg) | |
| VB19055 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| VCT220 | Phase 2 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| BEBT-701 | Phase 1/2 | RNA / oligonucleotide | Angiotensinogen (AGT) / PCSK9 (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| ADX-850 | Phase 1 | RNA / oligonucleotide | Angiotensinogen (AGT) | not yet graded | No reviewed efficacy summary in this indication | |
| Carvedilol (CKD-385) | Phase 1 | Small molecule | Beta-adrenergic receptors (nonselective) and alpha-1 adrenergic receptor (antagonist) | Partial signal | No reviewed efficacy summary in this indication | |
| HJB647 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| HS-10522 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| JX09 | Phase 1 | Small molecule | Aldosterone synthase (CYP11B2) | Partial signal | No reviewed efficacy summary in this indication | |
| KK3910 | Phase 1 | Biologic (subtype unspecified) | — | not yet graded | No reviewed efficacy summary in this indication | |
| KN060 | Phase 1 | Monoclonal antibody | Factor XI/XIa (FXI/FXIa) | not yet graded | No reviewed efficacy summary in this indication | |
| LivaloV | Phase 1(overall) | Small molecule | HMG-CoA reductase / Angiotensin II type 1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Long-Acting ANP Analog (LY3971297) | Phase 1 | Peptide | Natriuretic peptide receptor (NPR-A) | not yet graded | No reviewed efficacy summary in this indication | |
| Nurandociguat | Phase 1 | Small molecule | Soluble guanylate cyclase | Weak signal | No reviewed efficacy summary in this indication | |
| SHR-4658 | Phase 1(overall) | Peptide | — | not yet graded | No reviewed efficacy summary in this indication | |
| C2402 | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Candesartan / Amlodipine | —(overall) | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel | not yet graded | No reviewed efficacy summary in this indication | |
| DehydraTECH-CBD | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Lercanidipine | —(overall) | Small molecule | L-type calcium channels (Cav1.2) | not yet graded | No reviewed efficacy summary in this indication | |
| OLOMAX | —(overall) | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Rosuampin | —(overall) | Small molecule | HMG-CoA reductase / Calcium channel | not yet graded | No reviewed efficacy summary in this indication | |
| N0877 | Discontinued | Small molecule | Angiotensin II receptor / Thiazide diuretic | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.